Skip to content
Contactez-nous: (+33) 1 64 62 10 12
Theradiag
  • Home
  • Company
    • About us
    • Our history
    • Board of directors
    • Our management team
    • Know-how
    • Privacy policy
  • Theranostic
    • Therapeutic Drug Monitoring of Biologics
      • When to perform TDM ?
      • Results interpretation
      • Therapeutic Thresholds
      • Tracker Publications
      • Guidelines
      • Frequently asked questions
    • TRACKER
      • LISA TRACKER
      • i-Tracker
      • i-Track 10
      • ez-Track1 & ez-Tracker
      • Immunotrol Tracker
    • Patient Stratification – PredictImmune
    • American Customers
  • Diagnostics
    • Autoimmunity
      • Reagents – Autoimmunity
      • Quality Control – Auto-Immunity
    • Other fields
    • Instrumentation
      • Theralis
      • FIDIS™
  • Services
    • Technical Documentation Download Center
  • News
    • Press Releases
    • List of upcoming events
    • Congress calendar
  • Investors
    • Welcome Message
    • Financial News
      • Register to receive our latest news
      • Press Releases
      • Financial Reports
      • Financial presentations
    • Shareholder information
      • Stock information
      • Shareholding
      • Analyst coverage
      • Letters to shareholders
      • General meeting
    • Regulated information
      • Share capital and voting rights
      • Corporate governance & internal control
      • Statutory auditors fees
      • Description of the buyback program
      • Prospectus
      • Share buyback statement
      • Charters and code of ethics / Anti-corruption
      • Other regulated information
    • Governance
      • Board of directors
      • Our management team
      • Statute and internal regulations
      • Quiet period policy and trading windows
    • Investor contacts and registration
    • Legal notice
  • Contacts
  • Français
  • English
Menu Close

Charters and code of ethics / Anti-corruption

  1. Home>
  2. Investors>
  3. Regulated information>
  4. Charters and code of ethics / Anti-corruption

Latest Press Releases

  • 18/09/2023: Theradiag announces its 2023 half-year results and reports a significant improvement in profitability
    18 September 2023/
    0 Comments
  • 17/07/2023: Theradiag reports revenue for the first half 2023
    17 July 2023/
    0 Comments
  • 12/04/2023: Theradiag announces its 2022 full-year results and 2023 first quarter revenue
    12 April 2023/
    0 Comments

Events

25 - 28 Sep 2023

EURACHEM PT 2023

De Vere Beaumont Estate hotel
27 - 29 Sep 2023

28th FFER days

Palais des Congrès d'Arcachon
29 - 30 Sep 2023

12th MICI ouest days

Couvent des Jacobins
No event found!
Load More

Next financial Event

No event found!

Useful links

  • Diagnostic
  • Theranostic
  • Events
  • Register to receive our latests news

Contact Information

  • Address:14, Rue Ambroise Croizat, 77183 Croissy Beaubourg, France
  • Phone:+33 1 64 62 10 12
  • Email:info@theradiag.comOpens in your application

Follow Us

Theradiag ©
  • Home
  • Company
    • About us
    • Our history
    • Board of directors
    • Our management team
    • Know-how
    • Privacy policy
  • Theranostic
    • Therapeutic Drug Monitoring of Biologics
      • When to perform TDM ?
      • Results interpretation
      • Therapeutic Thresholds
      • Tracker Publications
      • Guidelines
      • Frequently asked questions
    • TRACKER
      • LISA TRACKER
      • i-Tracker
      • i-Track 10
      • ez-Track1 & ez-Tracker
      • Immunotrol Tracker
    • Patient Stratification – PredictImmune
    • American Customers
  • Diagnostics
    • Autoimmunity
      • Reagents – Autoimmunity
      • Quality Control – Auto-Immunity
    • Other fields
    • Instrumentation
      • Theralis
      • FIDIS™
  • Services
    • Technical Documentation Download Center
  • News
    • Press Releases
    • List of upcoming events
    • Congress calendar
  • Investors
    • Welcome Message
    • Financial News
      • Register to receive our latest news
      • Press Releases
      • Financial Reports
      • Financial presentations
    • Shareholder information
      • Stock information
      • Shareholding
      • Analyst coverage
      • Letters to shareholders
      • General meeting
    • Regulated information
      • Share capital and voting rights
      • Corporate governance & internal control
      • Statutory auditors fees
      • Description of the buyback program
      • Prospectus
      • Share buyback statement
      • Charters and code of ethics / Anti-corruption
      • Other regulated information
    • Governance
      • Board of directors
      • Our management team
      • Statute and internal regulations
      • Quiet period policy and trading windows
    • Investor contacts and registration
    • Legal notice
  • Contacts
  • Français
  • English